Viiv Healthcare’s cabotegravir effective in HIV prevention in women
November 9, 2020Sales and Marketing AIDS, HIV
Viiv Healthcare’s cabotegravir is more effective in preventing HIV in women than the oral standard of care, according to an …
China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer
November 6, 2020Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi
China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …
Johnson & Johnson and three drug distributors close to $26 billion settlement
November 6, 2020Medical Communications
Johnson & Johnson, McKesson, Cardinal Health and AmerisourceBergen are close to a $26 billion deal with local and state governments …
US Department of Justice looking into Pfizer’s operations in China
November 6, 2020Medical Communications
The US Department of Justice and the US Securities and Exchange Commission (SEC) are investigating Pfizer’s operations in China after …
Novartis’ arthritis therapy shows no efficacy in hospitalised COVID-19 patients
November 6, 2020Medical Communications, Research and Development COVID-19, Novatis, canakinumab
Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to …
Pharmafile.com’s weekly COVID-19 news round-up
November 6, 2020Medical Communications COVID, COVID-19, EC, FDA, coronavirus
The top ten news stories this week focus on regulatory approvals as the European Commission has approved GlaxoSmithKline’s Zeljula as …
Australia secures a further 50m COVID-19 vaccine doses from Novavax and Pfizer/BioNTech
November 5, 2020Manufacturing and Production Australia, COVID-19, Vaccine
Two more COVID-19 vaccine distribution deals have been signed by the Australian Government, reserving a further 50 million doses to …
Biogen’s Alzheimer’s drug expected to be approved by the FDA after successful late-stage trial
November 5, 2020Business Services
Biogen’s Alzheimer’s drug aducanumab is on track to be approved by the FDA after a successful late-stage clinical trial. The …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
November 5, 2020Sales and Marketing BMS, Cancer, NHS, NICE, opdivo
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …
Psilocybin has substantial antidepressant effects according to a new study
November 5, 2020Business Services
Psilocybin has substantial and enduring antidepressant effects, according to a new study conducted by a team at John Hopkins University. …
Denmark set to cull mink population after mutated strain of COVID-19 spreads to humans
November 5, 2020Business Services
Denmark is set to cull its 17 million mink population after it was found a mutation of coronavirus in the …
How the US election could affect the pharmaceutical industry
November 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Donald Trump, Joe Biden, Trump, US, US election 2020, pharma
The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of …
Pharmafile.com’s weekly COVID-19 news round-up
November 4, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir
As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …
Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis
November 4, 2020Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis
Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …
Nostrum Laboratories recalls metformin tablets over safety concerns
November 4, 2020Manufacturing and Production, Research and Development Nostrum laboratories, metformin, recall
Missouri-based Nostrum Laboratories has issued a product recall of its type 2 diabetes drug metformin to the FDA over concerns …
J&J’s appeal shot down over $2.12m payment due to allegedly carcinogenic talc products
November 4, 2020Research and Development, Sales and Marketing J&J, JJ, baby powder, ovarian cancer, talc
Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …
Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis
November 4, 2020Research and Development BMS, deucravacitinib, plaque psoriasis
Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …
Regeneron halts Phase 1 study into ultra-rare disease due to patient deaths
November 3, 2020Manufacturing and Production, Research and Development Regeneron, clinical trials, garetosmab, pharma
Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …
UCB Pharma’s bimekizumab improves skin clearance over Humira in plaque psoriasis
November 3, 2020Manufacturing and Production, Research and Development UCB Pharma, bimekizumab, pharma
In recent Phase 3 study data presented European Academy of Dermatology and Venereology Congress last weekend, UCB Pharma reported that …
T-cells respond to COVID-19 six months after infection
November 3, 2020Manufacturing and Production
There is evidence that human T-cells can respond to coronavirus six months after the body is initially infected, according to …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
